From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
Sings | vitamin D level | Significance of differences | |
---|---|---|---|
before additional intake of vitamin D | after taking of vitamin D | ||
general group | 21,40±1,97 | 28,89±2,11 | p<0,05 |
normal BMI | 22,57±3,94 | 27,08±5,47 | p<0,05 |
decreased BMI | 17,69±3,15 | 30,01±6,26 | p<0,05 |
increased BMI | 25,02±5,73 | 25,72±4,74 | p>0,05 |
oligoarthritis | 24,69±1,89 | 31,42±2,30 | р<0,05 |
polyarthritis | 18,03±2,25 | 24,21±2,74 | р>0,05 |
undifferentiated arthritis | 22,24±2,46 | 25,32±3,01 | р>0,05 |
inactive disease | 22,56±4,95 | 24,57±5,87 | p>0,05 |
moderate activity | 25,38±3,78 | 25,56±3,79 | p>0,05 |
average activity | 25,45±3,89 | 30,35±4,78 | p<0,05 |
high activity | 22,49±3,45 | 27,61±4,12 | p<0,05 |
MTX + | 21,53±7,16 | 29,03±9,99 | p<0,05 |
MTX - | 22,67±2,86 | 23,03±3,42 | p>0,05 |
Duration of MTX therapy: | |||
 before 6 months | 22,98±2,71 | 31,86±6,28 | p<0,05 |
 7-12 months | 21,27±3,24 | 28,82±8,34 | p>0,05 |
 1-2 years | 20,50±3,03 | 25,16±10,40 | p>0,05 |
 3-5 years | 20,87±2,71 | 21,53±3,74 | p>0,05 |
Doses of MTX: | |||
 less than 10 mg/m2 | 22,37±2,67 | 22,99±2,45 | p>0,05 |
 10,1-12,4 mg/m2 | 21,09±2,78 | 32,22±3,74 | p<0,05 |
 12,5-15 mg/m2 | 22,31±2,36 | 30,71±3,46 | p<0,05 |